Paul Koller, M.D.
Hematologist-Oncologist
4.9 (94 RATINGS)
Clinical Expertise
Leukemia
Research Area
Hematology and Hematopoietic Cell Transplantation
Leukemia
Appointments
Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Acute Myeloid Leukemia
Hematology & Hematopoietic Cell Transplantation
Leukemia
Myelodysplastic Syndrome
Dr. Paul Koller is an Assistant Professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Leukemia at City of Hope Comprehensive Cancer Center in Duarte, California. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute and chronic leukemia, including biologically rational targeted therapy and novel combination therapies. He is a primary investigator on numerous trials in chronic myeloid leukemia, acute myeloid leukemia, acute lymphoid leukemia, and high-risk myelodysplastic syndrome.
Location
Duarte Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Duarte, CA 91010
Education & Experience
2018 American Board of Internal Medicine- Hematology
2018 American Board of Internal Medicine- Medical Oncology
2015 American Board of Internal Medicine- Internal Medicine
2012, M.D., Medicine, University of Texas, Houston, TX
2015-2018, Hematology/Oncology Fellow, Supervisor: Robert Wolff, M.D., Department of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX
2012-2015, Internal Medicine, Supervisor: Richard Hamill, M.D., Department of Internal Medicine, Baylor College of Medicine Affiliated Hospitals, Houston, TX
2019-present, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2018-2019, Instructor, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
Awards & Memberships
Awards
2018, Conquer Cancer Foundation of ASCO/Texas Society of Clinical Oncology Young Investigator Award
2018, Top recipients of the 2018 TxSCO Fellows Research Competition
Publications
- Amanam I, Yao J, Puing A, Tsai NC, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki MM. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med. 2023 May;12(10):11248-11253. doi: 10.1002/cam4.5832. Epub 2023 Apr 20. PMID: 37081733; PMCID: PMC10242327.
- Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Post-Transplantation Sinusoidal obstruction syndrome in adult patients with B cell acute lymphoblastic leukemia treated with pretransplantation Inotuzumab. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19.PMID:36682470
- Tinajero J, Koller P, Ali H. Ponatinib, Asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia. Leuk Res. 2023 Apr 23;129:107299. doi: 10.1016/j.leukres.2023.107299. Online ahead of print.PMID:37120933
- Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 Apr 13;141(15):1884-1888. doi: 10.1182/blood.2022017686.PMID:36332187
- Amanam I, Yao J, Puing A, Tsai NC, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki MM. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective since center experience. Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5832. Online ahead of print.PMID:37081733
- Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26908. Online ahead of print.PMID:36880203
- Ball, BJ*, Arslan, S*, Koller, P*,et al. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged Acute Myeloid Leukemia (AML). Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.PMID:36089918
- Ball BJ, Koller PB, Pullarkat, V. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Curr Opin Oncol. 2022 Sep 1;34(5):531-539. doi: 10.1097/CCO.0000000000000868. Epub 2022 Jul 16.PMID:35855507
- Ngo D, Samuels D, Chen J, Koller PB, Al Malki MM. A Clinical Review of the Different strategies to minimize Hemorrhagic Cystitis associated with the use of Post-transplantation Cyclophosphamide in an Allogeneic Transplant. Transplant Cell Ther. 2022 Jul;28(7):349-354. doi: 10.1016/j.jtct.2022.05.012. Epub 2022 May 14.PMID:35580733
- Aldoss I, Yang D, Tomasian V, Mokhtari S, Jackson R, Gu Z, Telatar M, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei MG, Arslan S, Koller PB, Artz AS, Aoun P, Gu D, Snyder DS, Stewart F, Curtin PT, Stein AS, Pillai RK, Marcucci G, Forman SJ, Pullarkat VA, Nakamura R, Afkhami M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Fusions Associated with Ph-like ALL. Blood Adv. 2022 Sep 13;6(17):4936-4948. doi: 10.1182/bloodadvances.2022007597.PMID:35816633
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
Ratings
5.0
Provider explain in way you understand
5.0
Provider listen carefully to you
4.9
Recommend this provider office
4.9
Know important info medical history
4.9
Show respect for what you say
4.9
Spend enough time with you
4.9
Rate provider 0-10
Reviews
05/01/24
Very easy to talk with. Makes me very comfortable to speak openly. - Verified patient
05/01/24
Excellent Dr. Discusses options and thoughts on my treatment. Makes me feel hopeful about my future. - Verified patient
01/01/24
Dr. Koller is always generous with his time and provides empathic advice and care. - Verified patient
12/08/23
Dr. Koller and team are very helpful and put me to ease. - Verified patient
11/27/23
Audio and video was good. - Verified patient